This study looks at a new treatment called firi-cel for a type of blood cancer known as large B-cell lymphoma (LBCL). Firi-cel uses a special type of immune cell called CAR T-cell to target and attack cancer cells. The study is for patients whose cancer has come back or not responded to other treatments. Up to 123 patients will receive one dose of this therapy to see if it is safe and effective.
- You must stay close to the treatment center for the first 4 weeks after receiving the treatment.
- The study requires you to have had previous CAR T-cell therapy or other specific cancer treatments.
- Participants should not have serious other illnesses or active infections.
How understandable was the trial content above?
Hard to understand
Easy to understand